⌕
Xencor · XNCR · Nasdaq
Tenet 40 · Weak
Compare
$34.50−2.54%At closeTenet 40 · Weak
$34.50−0.90 (−2.54%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Xencor (XNCR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is XNCR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 9, 2026 · 08:01 ETCOMPANY'S OWN WORDS
Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial dose…

XNCR −2.5% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 18:51 ETEARNINGS EXPECTED BY FEB 25
Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates

Xencor (XNCR) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.08 per share a year ago.…

XNCR −2.5% todayRead at source ↗
● Business WireNov 4, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 25
Xencor Reports Third Quarter 2026 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial res…

XNCR −2.5% todayRead at source ↗
● Seeking AlphaOct 26, 2026 · 15:22 ETEARNINGS EXPECTED BY FEB 25
Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway

Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. XmAb819 achieved a 45.5% cORR at 400 mcg/kg, supporting advancement towa…

XNCR −2.5% todayRead at source ↗
● MarketBeatOct 26, 2026 · 15:02 ETEARNINGS EXPECTED BY FEB 25
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer

Xencor NASDAQ: XNCR reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The com…

XNCR −2.5% todayRead at source ↗
● Seeking AlphaOct 26, 2026 · 13:09 ETEARNINGS EXPECTED BY FEB 25
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript…

XNCR −2.5% todayRead at source ↗
● BenzingaOct 26, 2026 · 13:00 ETEARNINGS EXPECTED BY FEB 25
Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

At the ESMO Congress 2026, Xencor Inc. (NASDAQ:XNCR) shared updated results from the Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC).…

XNCR −2.5% todayRead at source ↗
● Business WireOct 25, 2026 · 04:35 ETCOMPANY'S OWN WORDS
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated resu…

XNCR −2.5% todayRead at source ↗
● Business WireOct 19, 2026 · 07:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 25
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monda…

XNCR −2.5% todayRead at source ↗
● Defense WorldSep 30, 2026 · 06:21 ET
Xencor (NASDAQ:XNCR) Shares Up 4.6% – What’s Next?

Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) were up 4.6% during mid-day trading on Monday. The company traded as high as $24.66 and last traded at $24.8920. 290,326 shares were traded during trading, a declin…

XNCR −2.5% todayRead at source ↗
● Defense WorldSep 28, 2026 · 03:25 ETEARNINGS EXPECTED BY FEB 25
Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE

Bank of America Corp DE bought a new stake in shares of Xencor, Inc. (NASDAQ: XNCR) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 360,396 shares of the biopharmaceutica…

XNCR −2.5% todayRead at source ↗
● Defense WorldSep 18, 2026 · 03:18 ET
Xencor (NASDAQ:XNCR) versus Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Contrast

Anika Therapeutics (NASDAQ: ANIK - Get Free Report) and Xencor (NASDAQ: XNCR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the st…

XNCR −2.5% todayRead at source ↗
● Defense WorldSep 4, 2026 · 03:50 ETEARNINGS EXPECTED BY FEB 25
Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR

Bank of New York Mellon Corp acquired a new position in shares of Xencor, Inc. (NASDAQ: XNCR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commis…

XNCR −2.5% todayRead at source ↗
● Business WireSep 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Xencor to Present at the 2026 Cantor Global Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company…

XNCR −2.5% todayRead at source ↗
● Defense WorldAug 18, 2026 · 03:42 ET
Xencor (NASDAQ:XNCR) Sets New 52-Week High – Should You Buy?

Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $23.47 and last traded at $23.12, with a volume of 962153 shares trading hands. The st…

XNCR −2.5% todayRead at source ↗

Expected by Feb 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just XNCR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.